Study: Tradjenta reduces blood sugar, weight among patients
SAN DIEGO — New data from a late-stage clinical trial of a recently approved drug for Type 2 diabetes show improved blood-sugar control in adults who take it with metformin or alone.
Boehringer Ingelheim and Eli Lilly presented data from the study of Tradjenta (linagliptin) at the American Diabetes Association’s 71st Scientific Sessions in San Diego last weekend. The study showed reductions in blood sugar and weight, and a low incidence of abnormally low blood sugar, known as hypoglycemia.
The FDA approved Tradjenta as a treatment for Type 2 diabetes in May.
Gilead, Tibotec to develop HIV drug
CORK, Ireland — A subsidiary of Johnson & Johnson and Gilead Sciences will collaborate to develop a combination drug for HIV, the two companies said Tuesday.
Gilead and Tibotec Pharmaceuticals will work to create a once-daily, single-tablet combination of Tibotec’s Prezista (darunavir) and Gilead’s investigational drug cobicistat, a so-called boosting agent.
“We are excited to be able to study and develop Prezista with an alternative boosting agent in a combination product that has the potential to reduce the number of tablets patients take,” said Johan Van Hoof, global therapeutic area head for infectious diseases and vaccines for Janssen Pharmaceutica, another subsidiary of J&J that is Tibotec’s parent.
Lyxumia demonstrates noninferiority to Byetta in late-stage trial
PARIS — An investigational Sanofi drug for diabetes works at least as well as a similar treatment already on the market, and results in less abnormally low blood sugar, according to late-stage clinical trial results presented at the American Diabetes Association’s 71st Scientific Sessions in San Diego this past weekend.
Sanofi said the drug Lyxumia (lixisenatide) demonstrated noninferiority to Byetta (exenatide), made by Eli Lilly and Amylin Pharmaceuticals, and less hypoglycemia in a phase-3 trial. The trial included 634 patients who received either Lyxumia once per day or Byetta twice per day in addition to the generic diabetes drug metformin.
Other findings included greater reduction in weight and fewer patients having to stop therapy due to such adverse side effects as nausea, diarrhea and vomiting.